Protalix Biotherapeutics PLX 深 沪
等待开盘 12-16 09:30:00 美东时间
1.74
-0.050
-2.79%
华盛通- 最 高1.80
- 今 开1.80
- 成交量 33.33万股
- 最 低 1.72
- 昨 收 1.79
- 总市值 1.39亿
- 52周最高 3.10
- 市盈率 静 47.54
- 换手率 0.42%
- 52周最低 1.32
- 委 比 -6.67%
- 总股本 7973.21万
- 历史最高 77.00
- 量 比 0.67
- 振 幅 4.47%
- 历史最低 0.70
- 每 手 1
- 风险率 0.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
11-24 11:23
Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer
Nasus Pharma Ltd. has appointed Eyal Rubin as its Chief Financial Officer, bringing over two decades of experience in the biotech and pharma industries. Rubin will oversee financial operations, planning, and investor relations as the company advances its intranasal therapeutics. His expertise is expected to bolster the company's growth and strategy execution.
11-20 13:15
Protalix BioTherapeutics Q3 EPS $0.03 Misses $0.06 Estimate, Sales $17.673M Miss $17.866M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.06 by 45.45 percent. This is unchanged from the same period last year. The company
11-13 19:51
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
Protalix Seeks EMA Re-examination for Elfabrio Dosing
Protalix ( ($PLX) ) has issued an update. On November 3, 2025, Protalix BioTher...
11-04 06:10
Protalix BioTherapeutics Unit Requests Reexamination Of Negative Opinion Issued By CHMP Related To Proposed Dosing Regimen Of 2 Mg/kg Body Weight Infused Every 4 Weeks For Elfabrio
Chiesi Global Rare Diseases, a business unit of the Chiesi Group, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), have requested a re-examination of the recent negative opinion issued by the Committee for
11-04 05:33
Why Is Protalix BioTherapeutics Stock Falling On Friday?
EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.
10-17 23:23
Protalix Faces EMA Setback on Elfabrio® Dosing
Protalix ( ($PLX) ) has issued an announcement. On October 17, 2025, Protalix B...
10-17 20:27
Vantage Drilling International Ltd. Announces Contract for Platinum Explorer
Dubai, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Vantage Drilling International Ltd. (...
09-09 23:06
Protalix BioTherapeutics Q2 Sales $15.658M Beat $13.546M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly sales of $15.658 million which beat the analyst consensus estimate of $13.546 million by 15.59 percent. This is a 16.21 percent increase over sales of $13.474
08-14 18:51
